TNF-α blockers, or anti-TNF-α (aTNF-α), have been involved in the treatment of psoriasis vulgaris, rheumatoid arthritis, and inflammatory bowel disease and were recently approved for hidradenitis suppurativa. This evidence concerns the gene TNF and psoriasis vulgaris.